New patient data surrounding the medication Retatrutide , specifically the high-dose formulation ZPHC ZPHC, suggest a considerable effect on body mass decrease and related metabolic illnesses . Scientists posit that this dual compound, influencing both GLP-1 and GIP systems, has the potential to provide a substantial breakthrough in the management